TY - JOUR
T1 - Changes in local tissue microenvironment in response to subcutaneous long-acting delivery of tenofovir alafenamide in rats and non-human primates
AU - Pons-Faudoa, Fernanda P.
AU - Di Trani, Nicola
AU - Capuani, Simone
AU - Hernandez, Nathanael
AU - Wood, Anthony M.
AU - Nehete, Bharti
AU - Niles, Jean
AU - Shelton, Kathryn A.
AU - Kezar, Sarah
AU - Bushman, Lane R.
AU - Chua, Corrine Ying Xuan
AU - Ittmann, Michael M.
AU - Anderson, Peter L.
AU - Nehete, Pramod N.
AU - Arduino, Roberto C.
AU - Nichols, Joan
AU - Grattoni, Alessandro
N1 - Funding Information:
Beside its use as a TAF-stabilizing excipient, UA is known to possess immunosuppressive properties. Trans-UA is endogenous in the skin, and it isomerizes to cis-UA upon absorption of UV-B radiation. Cis-UA interacts with skin fibroblasts, which alter the function of antigen-presenting cells (APCs), ultimately activating suppressor T cells [32]. Our rat study showed that increasing concentrations of trans-UA mildly mitigated inflammation from sustained tissue exposure to TAF [33]. Although there was no statistical significance in the histological scoring between both TAF-UA groups, there was a difference in implant reactivity grade. The TAF-UAhi group had an Spair score of 10.38 compared to TAF-UAlo score of 16.75, corresponding to moderate and severe reactivity, respectively. These results informed our choice of TAF-UAhi for the study in NHP. The negative Spair scoring obtained for the UA-implant group provided additional support for UA ability to mitigate FBR.This work was supported by Gilead Sciences, funding from the National Institutes of Health National Institute of Allergy and Infectious Diseases (R01AI120749; A.G.), and the National Institutes of Health National Institute of General Medical Sciences (R01GM127558; A.G.). A.G. is an inventor of intellectual property licensed by Semper Therapeutics. A.G. and P.L.A. receives grants and contracts from Gilead Sciences paid to their respective institutions. A.G. does not perform consulting activities. P.L.A. collects personal fees from Gilead Sciences. All other authors declare that they have no competing interests or consulting engagements.We thank Dr. Andreana L. Rivera, Yuelan Ren, and Sandra Steptoe from the research pathology core of Houston Methodist Research Institute. We thank Luke Segura, Dana Salazar, Matthew McAdams and Elizabeth Lindemann from the Michale E. Keeling Center for Comparative medicine and Research at UTMDACC for support in animal studies. We thank Jim Rooney, Michael Clarke, Rich Clark, Chelsea Snyder, Bhanu Singh, and Christian Callebaut from Gilead Sciences for helpful insight and discussions.
Funding Information:
This work was supported by Gilead Sciences , funding from the National Institutes of Health National Institute of Allergy and Infectious Diseases ( R01AI120749 ; A.G.), and the National Institutes of Health National Institute of General Medical Sciences ( R01GM127558 ; A.G.). A.G. is an inventor of intellectual property licensed by Semper Therapeutics. A.G. and P.L.A. receives grants and contracts from Gilead Sciences paid to their respective institutions. A.G. does not perform consulting activities. P.L.A. collects personal fees from Gilead Sciences. All other authors declare that they have no competing interests or consulting engagements.
Publisher Copyright:
© 2023
PY - 2023/6
Y1 - 2023/6
N2 - Several implantable long-acting (LA) delivery systems have been developed for sustained subcutaneous administration of tenofovir alafenamide (TAF), a potent and effective nucleotide reverse transcriptase inhibitor used for HIV pre-exposure prophylaxis (PrEP). LA platforms aim to address the lack of adherence to oral regimens, which has impaired PrEP efficacy. Despite extensive investigations in this field, tissue response to sustained subcutaneous TAF delivery remains to be elucidated as contrasting preclinical results have been reported in the literature. To this end, here we studied the local foreign body response (FBR) to sustained subdermal delivery of three forms of TAF, namely TAF free base (TAFfb), TAF fumarate salt (TAFfs), and TAFfb with urocanic acid (TAF-UA). Sustained constant drug release was achieved via titanium–silicon carbide nanofluidic implants previously shown to be bioinert. The analysis was conducted in both Sprague-Dawley (SD) rats and rhesus macaques over 1.5 and 3 months, respectively. While visual observation did not reveal abnormal adverse tissue reaction at the implantation site, histopathology and Imaging Mass Cytometry (IMC) analyses exposed a local chronic inflammatory response to TAF. In rats, UA mitigated foreign body response to TAF in a concentration-dependent manner. This was not observed in macaques where TAFfb was better tolerated than TAFfs and TAF-UA. Notably, the level of FBR was tightly correlated with local TAF tissue concentration. Further, regardless of the degree of FBR, the fibrotic capsule (FC) surrounding the implants did not interfere with drug diffusion and systemic delivery, as evidenced by TAF PK results and fluorescence recovery after photobleaching (FRAP).
AB - Several implantable long-acting (LA) delivery systems have been developed for sustained subcutaneous administration of tenofovir alafenamide (TAF), a potent and effective nucleotide reverse transcriptase inhibitor used for HIV pre-exposure prophylaxis (PrEP). LA platforms aim to address the lack of adherence to oral regimens, which has impaired PrEP efficacy. Despite extensive investigations in this field, tissue response to sustained subcutaneous TAF delivery remains to be elucidated as contrasting preclinical results have been reported in the literature. To this end, here we studied the local foreign body response (FBR) to sustained subdermal delivery of three forms of TAF, namely TAF free base (TAFfb), TAF fumarate salt (TAFfs), and TAFfb with urocanic acid (TAF-UA). Sustained constant drug release was achieved via titanium–silicon carbide nanofluidic implants previously shown to be bioinert. The analysis was conducted in both Sprague-Dawley (SD) rats and rhesus macaques over 1.5 and 3 months, respectively. While visual observation did not reveal abnormal adverse tissue reaction at the implantation site, histopathology and Imaging Mass Cytometry (IMC) analyses exposed a local chronic inflammatory response to TAF. In rats, UA mitigated foreign body response to TAF in a concentration-dependent manner. This was not observed in macaques where TAFfb was better tolerated than TAFfs and TAF-UA. Notably, the level of FBR was tightly correlated with local TAF tissue concentration. Further, regardless of the degree of FBR, the fibrotic capsule (FC) surrounding the implants did not interfere with drug diffusion and systemic delivery, as evidenced by TAF PK results and fluorescence recovery after photobleaching (FRAP).
KW - Foreign body response
KW - Immune microenvironment
KW - Long acting drug delivery
KW - Subcutaneous implants
KW - Tenofovir alafenamide
UR - http://www.scopus.com/inward/record.url?scp=85153863363&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85153863363&partnerID=8YFLogxK
U2 - 10.1016/j.jconrel.2023.04.037
DO - 10.1016/j.jconrel.2023.04.037
M3 - Article
AN - SCOPUS:85153863363
VL - 358
SP - 116
EP - 127
JO - Journal of Controlled Release
JF - Journal of Controlled Release
SN - 0168-3659
ER -